JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Sean Gaffney, Executive Vice President and Chief Legal Officer of Addus HomeCare Corp (NASDAQ:ADUS), sold 479 shares of the company’s common stock on February 25. The shares were sold at a price of $99.84 each, totaling $47,823. Following this transaction, Gaffney holds 18,179 shares directly. This sale was conducted under a 10b5-1 plan to cover tax obligations related to the vesting of restricted stock awards. According to InvestingPro’s analysis, Addus HomeCare maintains a GOOD financial health score, operating with moderate debt levels and sufficient cash flows to cover interest payments. For deeper insights into ADUS’s valuation and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Addus HomeCare Corporation reported its fourth-quarter 2024 earnings, surpassing expectations with an EPS of $1.38 compared to the forecasted $1.35, and revenue reaching $297.1 million against a forecast of $284.28 million. Despite these positive results, the company’s stock experienced a decline. The company’s recent acquisition of Gentiva and a rate increase in Illinois are expected to bolster earnings in the future. Analyst firms have made adjustments to their price targets for Addus HomeCare, with KeyBanc maintaining an Overweight rating and a $150 target, while Stephens cut its target to $142 but also maintained an Overweight rating. Raymond (NSE:RYMD) James reduced its price target to $120 from $140, citing concerns about potential Medicaid cuts, though it kept an Outperform rating. Addus HomeCare’s strategic focus on mergers and acquisitions remains strong, with a commitment to maintaining a growth trajectory despite potential legislative uncertainties. The company has also emphasized its insulation from potential Medicaid funding reforms, projecting minimal impact on its operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.